Edgewise Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
Date: March 3, 2025
| | | |
|---|---|---|
| | EDGEWISE THERAPEUTICS, INC. | |
| | | |
| | By: | /s/ Kevin Koch |
| | Name: | Kevin Koch |
| | Title: | President, Chief Executive Officer and Director |
| | | (Principal Executive Officer) |
Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.
| | | | | |
|---|---|---|---|---|
| Signature | Title | Date | ||
| | | | | |
| /s/ Kevin Koch | | President, Chief Executive Officer and Director | | March 3, 2025 |
| Kevin Koch, Ph.D. | | (Principal Executive Officer) | | |
| | | | | |
| /s/ R. Michael Carruthers | | Chief Financial Officer | | March 3, 2025 |
| R. Michael Carruthers | | (Principal Financial and Accounting Officer) | | |
| | | | | |
| /s/ Peter Thompson | | Co-Founder, Chairman and Director | | March 3, 2025 |
| Peter Thompson, M.D. | | | | |
| | | | | |
| /s/ Alan Russell | | Chief Scientific Officer and Director | | March 3, 2025 |
| Alan Russell, Ph.D. | | | | |
| | | | | |
| /s/ Laura A. Brege | | Director | | March 3, 2025 |
| Laura A. Brege | | | | |
| | | | | |
| /s/ Badreddin Edris | | Co-Founder and Director | | March 3, 2025 |
| Badreddin Edris, Ph.D. | | | | |
| | | | | |
| /s/ Jonathan Fox | | Director | | March 3, 2025 |
| Jonathan Fox, M.D., Ph.D., FACC | | | | |
| | | | | |
| /s/ Arlene Morris | | Director | | March 3, 2025 |
| Arlene Morris | | | | |
| | | | | |
| /s/ Jonathan Root | | Director | | March 3, 2025 |
| Jonathan Root, M.D. | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.